Unknown

Dataset Information

0

Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage.


ABSTRACT: BMS-955176 is a second-generation human immunodeficiency virus type 1 (HIV-1) maturation inhibitor (MI). A first-generation MI, bevirimat, showed clinical efficacy in early-phase studies, but ?50% of subjects had viruses with reduced susceptibility associated with naturally occurring polymorphisms in Gag near the site of MI action. MI potency was optimized using a panel of engineered reporter viruses containing site-directed polymorphic changes in Gag that reduce susceptibility to bevirimat (including V362I, V370A/M/?, and T371A/?), leading incrementally to the identification of BMS-955176. BMS-955176 exhibits potent activity (50% effective concentration [EC50], 3.9 ± 3.4 nM [mean ± standard deviation]) toward a library (n = 87) of gag/pr recombinant viruses representing 96.5% of subtype B polymorphic Gag diversity near the CA/SP1 cleavage site. BMS-955176 exhibited a median EC50 of 21 nM toward a library of subtype B clinical isolates assayed in peripheral blood mononuclear cells (PBMCs). Potent activity was maintained against a panel of reverse transcriptase, protease, and integrase inhibitor-resistant viruses, with EC50s similar to those for the wild-type virus. A 5.4-fold reduction in EC50 occurred in the presence of 40% human serum plus 27 mg/ml of human serum albumin (HSA), which corresponded well to an in vitro measurement of 86% human serum binding. Time-of-addition and pseudotype reporter virus studies confirm a mechanism of action for the compound that occurs late in the virus replication cycle. BMS-955176 inhibits HIV-1 protease cleavage at the CA/SP1 junction within Gag in virus-like particles (VLPs) and in HIV-1-infected cells, and it binds reversibly and with high affinity to assembled Gag in purified HIV-1 VLPs. Finally, in vitro combination studies showed no antagonistic interactions with representative antiretrovirals (ARVs) of other mechanistic classes. In conclusion, BMS-955176 is a second-generation MI with potent in vitro anti-HIV-1 activity and a greatly improved preclinical profile compared to that of bevirimat.

SUBMITTER: Nowicka-Sans B 

PROVIDER: S-EPMC4914680 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage.

Nowicka-Sans Beata B   Protack Tricia T   Lin Zeyu Z   Li Zhufang Z   Zhang Sharon S   Sun Yongnian Y   Samanta Himadri H   Terry Brian B   Liu Zheng Z   Chen Yan Y   Sin Ny N   Sit Sing-Yuen SY   Swidorski Jacob J JJ   Chen Jie J   Venables Brian L BL   Healy Matthew M   Meanwell Nicholas A NA   Cockett Mark M   Hanumegowda Umesh U   Regueiro-Ren Alicia A   Krystal Mark M   Dicker Ira B IB  

Antimicrobial agents and chemotherapy 20160620 7


BMS-955176 is a second-generation human immunodeficiency virus type 1 (HIV-1) maturation inhibitor (MI). A first-generation MI, bevirimat, showed clinical efficacy in early-phase studies, but ∼50% of subjects had viruses with reduced susceptibility associated with naturally occurring polymorphisms in Gag near the site of MI action. MI potency was optimized using a panel of engineered reporter viruses containing site-directed polymorphic changes in Gag that reduce susceptibility to bevirimat (inc  ...[more]

Similar Datasets

| S-EPMC4904268 | biostudies-literature
| S-EPMC8705664 | biostudies-literature
| S-EPMC4957142 | biostudies-literature
| S-EPMC10747836 | biostudies-literature
| S-EPMC5125710 | biostudies-literature
| S-EPMC3393465 | biostudies-literature
| S-EPMC3586122 | biostudies-literature
| S-EPMC7583898 | biostudies-literature
| S-EPMC3144912 | biostudies-literature
| S-EPMC6499332 | biostudies-literature